Cognixion and Pupil Labs Announce Strategic Partnership to Combine Eye-Tracking with Axon-R Neural Interface

Integration of Eye-Tracking and AI-Powered EEG BCI Technologies Opens New Frontiers for Clinical Researchers

SANTA BARBARA, Calif. and BERLIN – JUNE 4, 2025 — We’re excited to announce our partnership with Pupil Labs GmbH. By combining Cognixion’s noninvasive Brain-Computer Interface (BCI), Artificial Intelligence (AI), and Augmented Reality (AR) technologies with Pupil Labs’ advanced eye-tracking solutions, we’re creating a powerful new interface that measures both visual attention and neural signals. Their eye-tracking software will integrate with the Axon-R SDK, enabling seamless, cross-platform data collection and analysis.

High-precision eye tracking and advanced BCI electroencephalogram (EEG) capabilities will give clinical researchers powerful new tools for neuroscience, human-computer interaction, and assistive technology research. The combined technology will provide a higher level of data confidence, and a platform that can adapt to the unique needs of patients where disease progression may impact eye gaze ability, such as amyotrophic lateral sclerosis (ALS). The partnership addresses a significant need in the research community for unified tools that can simultaneously track visual attention and neural activity with research-grade precision.

"By combining Cognixion's neural interface expertise with Pupil Labs' industry-leading eye tracking technology, we're filling a critical role in sensor architecture that isn’t available with any current brain-computer interface technologies," said Andreas Forsland, CEO of Cognixion.

"This partnership enables a new generation of studies that can correlate visual attention with neural activity in real-time, potentially transforming our understanding of human cognition and interaction."

The integrated solution will allow researchers to:

● Rapidly prototype and deploy studies that simultaneously measure eye movements and brain activity

● Leverage research-grade sensors for both modalities without complex technical integration

● Access synchronized data streams through a unified developer interface

● Develop applications that respond to both visual attention and neural signals

"We've seen growing demand for combined eye-tracking and EEG solutions from our research partners," said Moritz Kassner, CEO of Pupil Labs. "This collaboration with Cognixion addresses that need with a seamless integration that maintains the fidelity researchers expect from both technologies while dramatically reducing technical barriers."

The integration is expected to be particularly valuable for clinical researchers studying attention, cognitive load, human-computer interaction, and assistive technologies for individuals with motor impairments.

Technical teams from both companies have begun the integration process, with initial releases expected within six months. The companies will also collaborate on joint marketing efforts and educational resources for the research community.

About Cognixion

Cognixion is a leader in brain-computer, augmented reality, artificial intelligence and natural user interface technology. The company is dedicated to improving the lives of individuals with severe motor impairments by providing cutting-edge patented technology that allows them to independently communicate and restore physical interactions with the world around them. The Cognixion ONE™ device is the company's flagship product, and it has already received significant recognition for its design and potential to transform the lives of individuals with severe motor impairments. Cognixion has received FDA Breakthrough Device Designation for its derivative version called Cognixion ONE Axon. The work described in this study is built upon the Cognixion ONE Axon-R, which is a version of the Axon made specifically for research purposes and is not currently cleared by the FDA as a medical device.

About Pupil Labs

Pupil Labs is a Berlin-based company that has been pioneering wearable eye-tracking technology since 2014. At the core of their platform is NeonNet, a state-of-the-art deep learning pipeline that delivers robust, calibration-free performance. NeonNet delivers rich data — gaze, pupil diameter, blinks, and more — with research-grade precision and reliability, setting a new benchmark for real-world eye tracking. Today, Pupil Labs supports a global community of over 10,000 professional users, with nearly 1,000 scientific publications produced using their tools.

http://pupil-labs.com/

For more information, please contact:

Ben Williamson – VP, Strategic Partnerships Cognixion Corporation (Connect with them here)

Marc Pieper- Product Lead & Partner, Pupil Labs GmbH (Connect with them here)

Cognixion Featured on CBS News

We’re excited to share that Cognixion was recently featured on CBS News & the Y-Axis, the tech and innovation newsletter by Yasmin Khorram.

In her latest post, “The Great Brain-Computer Race Heats Up,” Khorram dives into the fast-growing world of brain-computer interfaces (BCIs), where startups, tech giants, and researchers are racing to build the next generation of human-machine interaction tools.

We’re proud that Cognixion’s unique approach to BCI technology is included in this discussion — especially as a company focused on making this future accessible, non-invasive, and real-world ready today.

Our Vision: BCI Without Surgery

Unlike many players in the BCI space focused on implantable devices, Cognixion is building a wearable, AI-powered neural interface that combines:

• Non-invasive EEG

• Augmented reality

• Eye tracking and visual feedback

• Assistive communication tools

Our platform, Axon-R, is already in use by researchers and is currently being studied in an ongoing clinical trial with individuals living with ALS. The goal? To restore communication and connection, without the need for surgery.

A More Inclusive Neurotech Future

Khorram’s article explores the growing interest in BCI from companies like Neuralink and Precision Neuroscience, but it also shines a light on why accessibility matters in the rush to innovate.

“While many startups are pursuing surgically implanted devices, Cognixion is developing a non-invasive, wearable headset designed for people with speech and motor disabilities.”
— Yasmin Khorram, Play On

At Cognixion, we believe that the future of BCI should be inclusive, ethical, and designed with the end-user in mind, not only for labs but for everyday life.

📖 Read the full feature here:
The Great Brain-Computer Race Heats Up – Play On by Yasmin Khorram

🔬 Want to learn more about our clinical trial or research platform?
Explore Cognixion Axon-R

Cognixion and Blackrock Neurotech Expand Access to Non-Invasive, Multi-Modal BCI Research with Axon-R

Cognixion and Blackrock Neurotech Expand Access to Non-Invasive, Multi-Modal BCI Research with Axon-R

Blackrock Neurotech to begin immediate sales of Cognixion’s Axon-R wearable BCI + augmented reality platform, paving the way for integration of implantable BCI with immersive computing applications

Santa Barbara, CA — [5/14/25] — Cognixion, a leading developer of non-invasive brain-computer interface (BCI), artificial intelligence (AI) and augmented reality (AR) technology, today announced that Blackrock Neurotech, a leading developer of implantable BCIs, will offer Cognixion’s Axon-R wearable neural interface platform to research institutions through its distribution network.

Cognixion and Blackrock Neurotech maintain independent development activities but share a common vision: advancing the field of neurotechnology through expanded access to cutting-edge research tools. Under this offering, Blackrock Neurotech will act as a non-exclusive distributor of Cognixion’s Axon-R device, which is a non-invasive, wearable device that enables precise measurement and modulation of brain activity through visual stimuli, biofeedback, and neurofeedback, and is intended solely for investigational and educational use.

"This collaboration represents a powerful alignment of complementary technologies that will have an outsized impact across neurotechnology applications," said Andreas Forsland, CEO of Cognixion. "Blackrock Neurotech's implant technology combined with Cognixion's AI and augmented reality platform will open new doors for researchers and clinicians alike, while providing transformative solutions to the individuals we ultimately serve."

“At Blackrock Neurotech, our mission is restoring capability,” said Marcus Gerhardt, CEO of Blackrock Neurotech. “By expanding access to research-grade tools like Axon-R, we aim to support the early exploration of neural interfaces while maintaining our clinical focus on sovereign, high-fidelity implantable technologies that restore speech, movement, and sensation.”

The Axon-R system provides non-invasive brain monitoring capabilities that are ideal for foundational training and investigational research initiatives. While Blackrock Neurotech’s core focus remains on implantable, sovereign BCIs that restore speech, movement, and sensation, the availability of research-grade tools like the Axon-R opens new pathways for multidisciplinary innovation.

The immediate availability of Axon-R alongside clinical implantable solutions enables universities, hospitals, and academic programs to engage more deeply in BCI research, education, and investigational studies. By pairing Blackrock Neurotech’s implant technology with Cognixion’s Axon-R platform, researchers and hospitals can collect high-quality data from surface-level EEG alongside implanted BCI data in a time-synchronized manner. Early exposure to multi-modal, state-of-the-art BCI tools can empower clinical leaders to push the frontiers of medical science and patient care.

The Axon-R device is a research-grade, non-invasive BCI designed to support investigational use in neuroscience, neurorehabilitation, and education. The Axon-R is intended solely for research applications and is not cleared by the U.S. Food and Drug Administration (FDA) for clinical or therapeutic applications. Blackrock Neurotech acts solely as a distributor of the Axon-R for research use and does not develop, modify, or clinically endorse the device. Any future investigations involving multi-modal research across non-invasive and implantable systems are exploratory in nature and remain subject to independent validation.

About Cognixion:

Cognixion is a leader in brain-computer, augmented reality, artificial intelligence and neural user interface technology. The company is dedicated to improving the lives of individuals with severe motor impairments by providing cutting-edge patented technology that allows them to independently communicate and restore physical interactions with the world around them. The Cognixion ONE™ device is the company's flagship product, and it has already received significant recognition for its design and potential to transform the lives of individuals with severe motor impairments. Cognixion has received FDA Breakthrough Device Designation for its derivative version called, Cognixion ONE Axon. The work described in this study is built upon the Cognixion ONE Axon-R, which is a version of the Axon made specifically for research purposes and is not currently cleared by the FDA as a medical device.

About Blackrock Neurotech:

Blackrock Neurotech is a leading developer of implantable brain-computer interfaces (BCIs), empowering individuals and researchers to explore new frontiers in neuroscience and clinical care. Blackrock's technology has been at the forefront of breakthrough discoveries in human cognition and motor function restoration for over 15 years. 

For more information, please contact:

Ben Williamson – VP, Strategic Partnerships Cognixion Corporation (Connect with them here)

Gregory Palis – Director of Sales, Blackrock Neurotech (Connect with them here)

https://blackrockneurotech.com/

https://www.cognixion.com/

ALS News Today Spotlights Cognixion’s Clinical Trial for Non-Invasive BCI Headset

ALS News Today Spotlights Cognixion’s Clinical Trial for Non-Invasive BCI Headset

ALS News Today recently featured Cognixion in an article titled “Cognixion Seeks ALS Patients for Clinical Trial of BCI Headset”. The piece highlights our efforts to recruit participants living with ALS for a clinical study of our non-invasive brain-computer interface (BCI) headset, Cognixion ONE Axon.

This study represents a major step forward in our mission to deliver accessible communication technology to people with severe motor and speech impairments — and to validate it in partnership with the ALS community.

What the Study Involves

Our FDA Breakthrough Device–designated Cognixion ONE is a wearable headset that uses EEG brain signals, eye-tracking, augmented reality, and AI-assisted communication tools to enable users to speak and interact — even when traditional access methods are no longer possible.

This upcoming clinical trial will evaluate:

• The headset’s usability and comfort

• Its effectiveness in supporting communication

• The experience of individuals with ALS and related motor disabilities

“We’re focused on building technology that empowers people with ALS to express themselves independently — no surgery required.”
— Andreas Forsland, CEO & Founder of Cognixion

Why It Matters.

As ALS News Today reports, people with ALS often experience a progressive loss of motor and speech function. Existing communication devices may become too difficult to use over time, leaving individuals isolated.

Our headset was designed specifically to address that challenge — offering a hands-free, voice-free, surgery-free path to communication, built with direct feedback from individuals affected by ALS and their caregivers.

By participating in this study, individuals can help shape the next generation of non-invasive assistive technology — technology that could soon be available for real-world use in clinics, care facilities, and homes.

How to Get Involved

If you or someone you know is living with ALS and interested in participating, we encourage you to learn more:

🔗 Read the full article:
ALS News Today – Cognixion Seeks ALS Patients for Clinical Trial

📩 Learn more about the study or express interest:
https://clinicaltrials.gov/study/NCT06810219

IEEE Spectrum Highlights New Frontiers in ALS Communication

IEEE Spectrum Highlights New Frontiers in ALS Communication — and Cognixion is Proud to Be Part of the Movement

A recent article from IEEE Spectrum titled “How BCIs Are Helping People With ALS Communicate Again” offers a powerful look at the growing impact of brain-computer interface (BCI) technology on people living with ALS. We’re honored that Cognixion’s work is part of this important conversation.

ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that affects motor function, often leading to complete loss of speech and mobility. But thanks to advancements in neurotechnology — including both implantable and non-invasive BCIs — new doors are opening for individuals who once faced complete communication isolation.

Our Approach: Non-Invasive, Accessible, and Designed for Daily Life

At Cognixion, we’ve taken a different path from many BCI innovators. While some focus on surgically implanted systems, we’ve pioneered a wearable neural interface that combines non-invasive EEG, augmented reality (AR), and AI-powered assistive communication — no surgery required.

Our Cognixion ONE Axon system is designed specifically for individuals with severe speech and motor impairments, offering:

• 💬 Real-time communication via brain signals

• 🧠 Non-invasive EEG-based control

• 🕶️ An integrated AR display with eye-tracking and biofeedback

• 🌐 Tools for speaking, typing, and interacting with digital environments

Importantly, it's designed to be used at home, in clinics, and in everyday settings — putting powerful BCI tools into the hands of people who need them most, without the clinical barriers or surgical risks.

Why This Matters for ALS

As IEEE Spectrum notes, restoring communication for people with ALS is not just a technological challenge — it's a human rights issue. Every person deserves the ability to express themselves, connect with others, and maintain autonomy as their condition progresses.

That’s why we’ve built Cognixion ONE Axon and our research platform, Axon-R, with accessibility at the core. Our devices are developed in collaboration with people living with ALS and other neurodegenerative diseases, as well as their families, caregivers, and clinicians.

“The more we lower the barriers to communication, the more dignity, independence, and humanity we can help preserve.”
— Andreas Forsland, CEO & Founder of Cognixion

Moving Forward Together

We applaud the work of fellow innovators in the BCI space — including those featured in the IEEE article — who are pushing the limits of what's possible for people with ALS. Whether it’s through implants, wearables, or hybrid systems, our shared mission is to restore connection.

At Cognixion, we’re committed to developing solutions that are not just powerful, but practical, affordable, and ready for real-world use.

📖 Read the full IEEE Spectrum article here:
👉 How BCIs Are Helping People With ALS Communicate Again

🔍 Learn more about our open clinical trial:
👉 Click Here

Cognixion Featured in Forbes: Expanding Access to BCI Without Surgery

Check out our feature in Forbes for our work advancing non-invasive brain-computer interface (BCI) technology that empowers individuals with disabilities, without the need for surgery.

In the article, “This Startup Lets Paralyzed People Use Computers—Without a Chip in Their Head,” Forbes contributor Alex Knapp highlights how Cognixion’s Axon-R platform is changing the game for people with severe motor impairments by providing a wearable, AI-powered neural interface that works right out of the box.

🧠 No implants.
🕶️ No operating room.
💬 Just real-time communication and control through thought.

Making BCI More Accessible

At Cognixion, we believe brain-computer interface technology should be inclusive, affordable, and accessible.

Our Axon-R system combines:

• Non-invasive EEG sensors that read brain signals from the scalp

• Artificial intelligence to interpret intent and attention

• Augmented reality to provide a visual, interactive environment

• Assistive communication tools for real-time expression and interaction

As Forbes notes, what sets Cognixion apart is our focus on usability and accessibility, developed with and for people who live with ALS, cerebral palsy, spinal cord injuries, and other conditions that affect mobility and speech.

From Lab to Life

Many of the world’s leading BCI companies are developing powerful implantable systems — and we celebrate those advancements. But at Cognixion, our mission is to bring BCI technology out of the lab and into everyday life. That means designing devices that can be worn comfortably, used independently, and integrated into real-world environments like homes, schools, and care facilities.

Our flagship system, Cognixion ONE Axon, received FDA Breakthrough Device Designation and is undergoing further development for clinical applications. In parallel, our Axon-R platform is available today for research and investigational use — helping universities and healthcare institutions explore the future of multimodal neurotechnology.

Thank You, Forbes

We’re grateful to Forbes for spotlighting the progress being made in non-invasive BCI and for recognizing the importance of accessible innovation. The people we serve are not waiting for the future — they are building it with us.

📖 Read the full article here:
👉 This Startup Lets Paralyzed People Use Computers—Without a Chip in Their Head

Want to learn more or collaborate with us?
Visit www.cognixion.com to explore our research platform and assistive technologies.

Cognixion MedTech World Startup of the Year

🎥 Excited to share this video interview with our CEO Andreas Forsland at MedTech World Malta 2024! 🌍✨

During our time at the event, we explored how emerging technologies like #BCI, #AR, and #AI are transforming #Neurology and driving innovation in #SaMD and #HealthSystems. It was an incredible opportunity to connect with visionaries and showcase how platforms like ours are pushing the boundaries of what’s possible in healthcare.

A heartfelt thank you to Giovanni Lauricella, Yulia Yurevich, Dylan Attard MD, MRCSI, MEnt., and the entire team at MedTech World for coordinating such a phenomenal event and for making our visit unforgettable.

We are deeply honored to be recognized as the 2024 MedTech Startup of the Year, a milestone that underscores the dedication and passion of our entire team. 🙌💡

🚀 Watch the full interview here

To learn more about our work with the Cognixion ONE Axon-R hear to https://axon-r.cognixion.com/

#Neurology #SaMD #Platform #HealthSystems #BCI #AR #AI

AI for Good Summit: Cognixion One on One

New Video Alert! 🎥

Roll the clip from the AI for Good Global Summit, where our CEO @Andreas Forsland shares his exclusive perspectives! 🚀 Dive into his insight and discover key takeaways on advancing global development priorities through AI.

Check it out here:

We were honored to attend the AI for Good Global Summit which is the leading action-oriented United Nations platform promoting AI to advance health, climate, gender, inclusive prosperity, sustainable infrastructure, and other global development priorities. AI for Good is organized by the International Telecommunication Union (ITU) – the UN specialized agency for information and communication technology – in partnership with 40 UN sister agencies and co-convened with the government of Switzerland.

Don't forget to like, comment, and share your thoughts! Let's learn and grow together. 💡✨

#AssistiveTechnolofy #Learning #Growth #AIforGood #Innovation #GlobalDevelopment #Cognixion #AI #Technology

Cognixion: Pioneering a New Path in Brain-Computer Interface Adoption

Cognixion: Pioneering a New Path in Brain-Computer Interface Adoption

In the rapidly evolving field of brain-computer interfaces (BCIs), Cognixion is emerging as a formidable player, offering a distinct approach compared to its well-known rival, Neuralink. Backed by Amazon, Cognixion is dedicated to transforming the lives of individuals with disabilities through non-invasive BCI technology. Andreas Forsland, the founder and CEO of Cognixion, sheds light on the company's unique strategy and vision.

A Different Approach to BCI

While Neuralink, founded by Elon Musk, focuses on high-definition, implantable chips that require surgical procedures, Cognixion is taking a different route. Forsland emphasizes that Cognixion's non-invasive BCI headsets are designed to be accessible and practical for a broader audience. “Neuralink is an interesting technology, but it requires surgery, and most people are not going to volunteer for that,” Forsland told Observer. He added that only extreme use cases with high-needs neurological conditions would necessitate such invasive procedures, and most neurologists would avoid prescribing implants unless absolutely necessary.

Patient Advocacy Over Technology Investment

Cognixion's journey in the BCI space began in 2015, around the same time as Neuralink. However, Forsland points out a fundamental difference in their focus. “They focus much more on technology investment. We focus much more on patient advocacy,” he said. Cognixion aims to provide solutions that are less risky and more immediately beneficial to users. Their non-invasive headsets can unlock a variety of use cases, particularly in healthcare, by enabling speech through a speaker and a mirrored screen, accessing apps for home automation and entertainment, and tracking physiological data.

Strategic Partnerships and Clinical Collaborations

Cognixion's innovative approach has attracted significant investment from Amazon, which includes integrating Amazon Alexa technology into Cognixion devices. This integration allows patients to have full smart home controls, enhancing their independence and quality of life. Forsland also hinted at future partnerships with other major companies, further solidifying Cognixion's position in the market. On the clinical side, Cognixion's Axon-R is collaborating with prestigious institutions such as Johns Hopkins, Mass General, Northwell Health, Memorial Hermann Health System, and the Veterans Health Administration.

Scaling Impact and Regulatory Milestones

Forsland envisions a future where Cognixion's technology can scale to millions of people within years, not decades. The company has already received the FDA Breakthrough Device designation, which fast-tracks its approval process. Despite the regulatory challenges, Cognixion's products are already in clinical and laboratory use, and the company aims to become the first fully FDA-cleared BCI device.

Empowering Independence

The potential impact of Cognixion's technology extends beyond the individuals using it to their caregivers and families. Forsland explains, “Our system can enable individuals to be more independent of communication, smart home controls, mobility controls, where it reframes the role of the caregiver to a true companion versus somebody who just needs to suction a tracheostomy or turn on off the lights or change TV channels.” This ripple effect of increased independence and empowerment is at the heart of Cognixion's mission.

Conclusion

Cognixion is charting a new course in the BCI landscape, prioritizing patient advocacy and non-invasive solutions over high-risk, invasive procedures. With strategic partnerships, clinical collaborations, and a clear vision for the future, Cognixion is poised to make a significant impact on the lives of millions of people with disabilities. As Forsland aptly puts it, “If you think about a future where people are using their brain, especially people with disabilities, our technology can scale to millions of people within years, not decades”

Read the full article featured on Observer here

Mindblowing Neurotechnology, Cognixion CEO at Aspen Ideas Festival

Mindblowing Neurotechnology… 

featuring never before seen Cognixion ONE demos of our wearable BCI +AR system

Our CEO Andreas Forsland spoke about the work we are doing at Cognixion in AI-powered BCI with AR.  Specifically for enabling speech generation to those who are minimally or non-verbal due to an acquired or degenerative condition specifically the complete #ALS journey.

He spoke alongside: 

Thomas Oxley, MD - Neurologist Synchron- Creators of a implantable vascular brain sensor resembling a stent) 

Kate Rosenbluth, PhD, Associate Professor at Stanford, CEO Cala Health- Creators of a wearable wristband with electrical stimulation for essential tremors

Nita Farahany, Esq-Legal scholar, Ethicist at Duke University, Author of The Battle for Your Brain

Make sure to watch the whole special below to see never before seen demos of our wearable BCI+Augmented Reality system by ALS patients in various stages from early (cervical control), mid (visual/eye control), and late stage/locked-in stage (mental attention control) using it to communicate.

To learn more about Cognixion ONE or to sign up to be first in line for updates head over to https://one.cognixion.com/ and sign up at the bottom to join our Cognixion community!

Cognixion Receives CMS Accreditation Allowing for Future Reimbursement Through Medicare & Medicaid

• CMS accreditation allows Cognixion Medicare billing privileges as a supplier of durable medical equipment, enabling financial accessibility for its forthcoming technologies. 

• Medicare & Medicaid provides financial support and access to quality healthcare to over 65 million Americans. 

• Over 8 million Americans with Disabilities rely on Medicare or Medicaid. 

• Cognixion recently received FDA Breakthrough Device Designation which accelerates its interactions with the FDA towards regulatory clearance. 

• Cognixion aims to become the first FDA cleared Brain Computer Interface with Augmented Reality device allowing fully paralyzed or locked-in patients to communicate using visual mental attention. 

• Cognixion ONE is the first and only wireless brain computer interface, integrated with augmented reality in one system. 

 
On the heels of announcing FDA Breakthrough Device designation, Cognixion®, a leading developer of noninvasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, announced today that it has been accredited by the Centers for Medicare & Medicaid Services (CMS) as a durable medical equipment supplier (DME). This accreditation paves the way for insurance reimbursement via Medicare, Medicaid and Private Insurance for durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS).  

The company’s flagship product, Cognixion ONE, is a revolutionary assisted reality device — the bionic combination of Context-Aware AI Language Models, Augmented Reality and Assistive Technology Access Methods — designed to help people with severe motor impairments communicate and interact more effectively and independently with the world around them. The device utilizes electroencephalogram (EEG) technology to provide a noninvasive brain-computer interface (BCI) enabling patients with advanced disease progression to communicate their responses with their thoughts and mental attention in a wearable, augmented reality headset.  

"CMS accreditation is another important milestone in our path to bringing Cognixion ONE to market and making it available to those most in need by way of insurance reimbursement." said Andreas Forsland, CEO and Founder of Cognixion. "Since day one, our company has been focused on accessibility and CMS accreditation will go a long way in making Cognixion ONE accessible to those that are unable to pay out of pocket." 

To receive DMEPOS accreditation, Cognixion met rigorous quality standards set forth by CMS, addressing factors such as product quality, business integrity, accountability, and performance management. With this accreditation in place, the company will be ready and able to accept insurance reimbursement immediately following FDA clearance and product launch. 

To learn more contact our media relations {meaghan@cognixion.com}, investor relations {chris@cognixion.com} or head to https://www.cognixion.com/press-kit-cognixion-one

About Cognixion® 

Cognixion is a leader in brain-computer, augmented reality, artificial intelligence, and natural user interface technology. The company is dedicated to improving the lives of individuals with severe motor impairments by providing cutting-edge patented technology that allows them to independently communicate and interact with the world around them. The Cognixion ONE™ device is the company's flagship product, and it has already received significant recognition for its design and potential to transform the lives of individuals with severe motor impairments. 

SOURCE: Cognixion  

Cognixion Receives FDA Breakthrough Device Designation

Cognixion Receives FDA Breakthrough Device Designation for its Brain-Computer Interface with Augmented Reality for Assistive Communication 

• U.S. FDA Breakthrough Device designations are granted to expedite the review of technologies with the potential to greatly impact those suffering from life threatening and debilitating diseases. 

• Cognixion ONE Axon aims to become the first FDA cleared device allowing fully paralyzed or locked-in patients to communicate via a noninvasive brain-computer interface. 

• With Breakthrough Device designation, Cognixion ONE Axon could become available sooner to help those most in need. 

• Cognixion ONE is the first and only wireless brain computer interface, integrated with augmented reality in one system 

Cognixion®, a leading developer of noninvasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, announced today that its flagship device, the Cognixion ONE™ Axon, has been granted U.S. Food and Drug Administration (FDA) Breakthrough Device designation. The designation will allow the company to streamline their development and validation process with prioritized interactive feedback from FDA review staff in preparation for regulatory submission. This special FDA Breakthrough designation is awarded to devices that demonstrate the potential to provide more effective treatment of life-threatening or irreversibly debilitating diseases or conditions for which no clear alternatives exist. 

The Cognixion ONE is a revolutionary assisted reality device — the bionic combination or AI, Augmented Reality and Assistive Technology — designed to help people with severe motor impairments communicate and interact more effectively and independently with the world around them. The device utilizes electroencephalogram (EEG) technology to provide a noninvasive brain-computer interface (BCI) enabling patients with advanced disease progression to communicate their responses with their thoughts and mental attention in a wearable, augmented reality headset. Integrating Artificial Intelligence (AI) such as GPT large language models that run on the device with contextual predictions, the device aims to rapidly support the user’s communication intentions and desired outcomes, providing suggestions that can be quickly selected and communicated audibly and visually on the front visor as a communication aid. 

The device has been specifically designed to help individuals with neurodegenerative conditions such as Amyotrophic Lateral Sclerosis, also known as ALS or Lou Gehrig’s disease and MND (Motor Neuron Disease) as well as acquired conditions such as traumatic injuries and cerebral palsy that result in severe motor impairments. At present, no such cleared device exists which can allow fully paralyzed or locked-in patients to communicate once the current standard of care, eye-tracking, is no longer usable for their disease state due to ocular motor decline.  

"This FDA Breakthrough Device designation is a significant milestone, and we are thrilled to receive it for our Cognixion ONE device," said Andreas Forsland, CEO and Founder of Cognixion. "It validates the potential of our technology to make a real difference in the lives of individuals with severe motor impairments and underscores the importance of how AI can be used to assist people in everyday situations. We are excited to continue our work to bring this life-changing technology to those who need it most." 

While a number of neurotech companies are developing invasive BCI technologies including Elon Musk’s Neuralink aimed at assisting patients with communication abilities, Cognixion’s device could be prescribed and utilized without the need for surgical procedures or significant training, providing a new level of independence and autonomy to individuals who have been unable to communicate effectively due to their conditions. With planned further development, Cognixion ONE could become a one-of-a-kind platform, aggregating additional inputs to restore life changing abilities that have been lost to people with loss of language or personal agency.   

About Cognixion® 

Cognixion is a leader in brain-computer, augmented reality, artificial intelligence and natural user interface technology. The company is dedicated to improving the lives of individuals with severe motor impairments by providing cutting-edge patented technology that allows them to independently communicate and interact with the world around them. The Cognixion ONE™ device is the company's flagship product, and it has already received significant recognition for its design and potential to transform the lives of individuals with severe motor impairments. 

Contact: 

Media 

Meaghan Azlein, Marketing Manager 

meaghan@cognixion.com 

Investor Relations 

Chris Ullrich 

chris@cognixion.com 

Cognixion 

24 East Cota Street, Suite 101 

Santa Barbara, CA 93101 

Cognixion at CES with Amazon

Cognixion seeks to help people worldwide who are affected by speech disabilities or cognitive impairments. The company provides affordable and accessible AI-based technologies like the Cognixion ONE “Assisted Reality” headset.

'Neurocareers: Doing the Impossible!'

Neurocareers: Doing the Impossible!

The Mind Behind Assisted Reality: Andreas Forsland

Hosted by The Institute of Neuroapproaches and its founder, Milena Korostenskaja, Ph.D.

Have you ever asked yourself: 'What new can I learn today?' and dedicated yourself to constantly growing and expanding your knowledge?

In this episode of 'Neurocareers: Doing the Impossible!', we bring you Andreas Forsland, the founder and CEO of Cognixion, a company that is leading the way in the field of Assisted Reality. To democratize technology and make it accessible to millions of people, Andreas and his team at Cognixion are using biological sensors and intuitive user interfaces, including brain-computer interfaces (BCIs) for augmented reality.

Andreas not only shares his journey as a successful entrepreneur in the field of neurotech, but also talks about his approach to life-long learning. He believes that starting each day with the question: 'What new can I learn today?' is a great way to continuously grow and progress, even if the day doesn't go as planned.

From creativity and the drive to optimize to the ability to listen and understand, he reveals the key components that have allowed him to succeed in neurotech. He also shares his insights on what he looks for in job applicants at Cognixion and what qualities he believes are essential for success in the field.

Join us as we explore the incredible potential of neurotech to make a difference in the lives of millions of people with disabilities and learn from Andreas how he is doing the impossible and changing lives through technology, all while continuously learning and growing. Tune in now to 'Neurocareers: Doing the Impossible!'

About the Podcast Guest:

Andrea Forsland is the Founder & CEO of Cognixion, the Assisted Reality company based in Santa Barbara, California and Toronto, Ontario. Cognixion ONE is a brain-computer interface that is integrated with an augmented reality display. It has wide-ranging implications as the foundational technology for a future metaverse where our mind and body are immersed in the user experience. Their primary focus is ensuring that the future of AR is universally accessible with the help of biological sensors and intuitive user interfaces and designed to assist millions of people with complex disabilities using their face, eyes, and now brain as a direct control interface for mobile and AR, and is addressing the needs of a half billion people worldwide with physical and communication challenges. Cognixion is recognized as a top 21 neurotech startup to watch, recently won the Red Dot Best of the Best Award for AR/VR and was nominated for the Red Dot Luminary Award, the Edison Award, and Singularity Global Grand Challenge, and is led by luminaries including the creator Siri, and signal processing sensor fusion for the Tricorder Xprize winner, plus multiple patents in the areas of natural user interfaces and brain-computer interface for augmented reality.

To learn more about Cognixion ONE: one.cognixion.com

Linktr.ee: Here

Cognixion LinkedIn: Here

Andreas’ LinkedIn: Here

About the Podcast Host:

The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a neuroscience educator, research consultant, and career coach for students and recent graduates in neuroscience and neurotechnologies. As a professional coach with a background in the field, Dr. K understands the unique challenges and opportunities facing students in this field and can provide personalized coaching and support to help you succeed.

Listen in here:

https://podcasts.apple.com/us/podcast/the-mind-behind-assisted-reality-andreas-forsland/id1512069366?i=1000599217220

Accessibility at CES: Featuring Cognixion ONE

CES was a blast 🚀 The team brought Cognixion ONE to the masses and everyone had great things to say!

Want an inside look? Hop over to the 9 minute mark to see Brad & Dan from All Access Life experience Cognixion ONE ✨ with our CEO Andreas Forsland

Want try out Cognixion ONE for yourself? Let us know at one.cognixion.com

#CES2023 #CES #accessibility #Cognixion #CognixionONE #A11y

Amazon Science Feature: Cognixion gives voice to a user’s thoughts

Cognixion gives voice to a user’s thoughts

Alexa Fund company’s assisted reality tech could unlock speech for hundreds of millions of people who struggle to communicate.

In 2012, Andreas Forsland, founder and CEO of Alexa Fund company Cognixion, became the primary caregiver and communicator for his mother. She was hospitalized with complications from pneumonia and unable to speak for herself.

“That experience opened my eyes to how precious speech really is,” Forsland says. According to a Cognixion analysis of over 1,200 relevant research papers, more than half a billion people worldwide struggle to speak clearly or at conversational speeds, which can hamper their interactions with others and full participation in society.

Forsland wondered whether a technology solution would be feasible and started Cognixion in 2014 to explore that possibility. “We had the gumption to think, ‘Wouldn’t it be neat to have a thought-to-speech interface that just reads your mind?’ We were naïve and curious at the same time.”

To read the full article head over to Amazon Science here

XR and Accessibility

Feature written by Shanna Finnigan of USCDornslife

One of the biggest contentions most critics have with Extended Reality is its lack of attention to accessibility. The fact of the matter is, it is not guaranteed that we can all use our senses to the same extent as everyone else around us; we will all therefore experience XR in different ways. Some are at an even bigger disadvantage due to issues in motor, visual, or auditory capabilities. XR is all about being able to engage with the world around you through your senses. It depends heavily on motion, visuals, and audio to create a memorable experience. So what happens when someone is unable to engage with this medium due to a disability?

VR and AR designers are entering the age of new mediums, in which the usual solutions we tend to have for accessibility are no longer as applicable. Dylan Fox and Isabel Thornton bring up a great example of this issue in their overview of ethical practices in the space: “features like captions are well understood on rectangular 2D screens but present many new challenges in XR” (IEEE Global Initiative). It has been challenging for designers to completely reimagine user interface and experience to accommodate as many people as possible. VR is already very taxing on the able body, but for people who have motor dysfunctions that either cause them to move their head non-stop or to be paralyzed, it is even more so. Many XR products have turned to eye-tracking as a method of solving this problem, but even this is not enough. Many people who have undergone strokes or who have developed ALS, for example, cannot move their eyes at all. Because we are so early in the process, not many solutions exist yet.  

Ventures like Cognixion are trying to change this. Cognixion is a growing company that specializes in “Assistive Reality” solutions. Their main product, Cognixion One, is an AR headset that aids in communication between users who are non-verbal (or cannot clearly communicate verbally) and other people, who may include their caretakers, family members, friends, etc. In a very simplified sense, this is how it works: there is an EEG at the back of each headset which is secured to the user’s head and reads the brain waves in their occipital lobe in the back of their head. On the sunglass-like frames in front of the user’s eyes, they are able to see a stereoscopic hologram-like projection of a keyboard and other UI elements. The EEG at the back of the headset is able to detect the most minute changes in brain activity, and deduct what letter the user is trying to look at on the display in front of them. Essentially, they are typing out words to the little computer inside their headset using their brain! Once fully formulated, the words are played back in the form of audio, and as a reflection on the front side of the shades on their headset. This way, whoever they are holding a conversation with can see and hear what the user is saying. 

The field of XR is growing rapidly, and with this fast growth, comes a responsibility of designers and engineers to be mindful of who they are designing for. 

For the full feature and to see more of Shanna’s great work head over to USCDornslife here